A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

Inclusion Criteria:

1. Have a diagnosis of ALL/LBL

2. Be > 1 to ≤ 21 years of age at study enrollment

3. Have had a ≥ Grade 2 allergic reaction (Common Terminology Criteria for Adverse
Events [CTCAE] v4.03) to pegaspargase

4. Have ≥ 1 dose(s) of pegaspargase remaining in his/her treatment plan

5. Have a documented SAA level that is below the limit of quantitation per the
analytical method.

6. Subjects must have, in the opinion of the investigator, fully recovered from prior
allergic reaction to pegaspargase. Subjects must have completed antihistamine,
epinephrine, and/or corticosteroid treatment for the allergic reaction ≥ 24 hours
prior to pegcrisantaspase administration.

7. Subjects must have a performance status corresponding to:

- Karnofsky ≥ 50 (for subjects > 16 years of age)

- Lansky ≥ 50 (for subjects ≤ 16 years of age)

8. Adequate Renal Function Defined as:

- Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2 or

- A serum creatinine based on age/gender as follows:

Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6
years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4

≥ 16 years 1.7 1.4

The threshold creatinine values in this table were derived from the Schwartz formula
for estimating GFR (Schwartz & Gauthier 1985) utilizing child length and stature data
published by the CDC.

9. Adequate Liver Function defined as:

Bilirubin levels ≤ 2.5x ULN for age, and Direct (conjugated) Bilirubin < 0.5
mg/dLSGPT (ALT) ≤ 225 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.

10. Subjects who are sexually active must agree to use a medically acceptable method of
contraception throughout the entire study period and for 4 weeks after the study is
completed. Medically acceptable methods of contraception that may be used by the
subject and/or the partner include abstinence, birth control pills or patches,
diaphragm and spermicide, condom and vaginal spermicide, surgical sterilization,
postmenopausal, vasectomy (>6 months prior to baseline), and progestin implant or
injection.

11. Able to understand and to sign a written informed consent. All subjects and/or their
parent or a legally authorized representative must sign a written informed consent.
Assent, when appropriate, will be obtained according to institutional guidelines.

Exclusion Criteria:

1. Have previously received Erwinia asparaginase

2. Are receiving another investigational agent or will receive an investigational agent
in subsequent phases of protocol therapy that include asparaginase

3. Have a history of ≥ Grade 3 pancreatitis (CTCAE v4.03)

4. Prior history of a CNS thrombotic event or ≥ Grade 3 (CTCAE v4.03) thrombotic event,
excluding catheter-associated clots

5. Prior history of asparaginase-associated ≥ Grade 3 (CTCAE v4.03) hemorrhagic event or
asparaginase-associated thrombus requiring anticoagulation therapy

6. Blood triglyceride levels > 500 mg/dL or > 5.6 mmol/L

7. Hyperglycemia requiring insulin therapy

8. QTc prolongation ≥ 550 msec

9. Subjects who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study

10. Subjects who have any serious active disease or co-morbid medical condition
(according to investigator's decision), or psychiatric illness that would prevent the
subject from signing the informed consent form, assent form or informed consent form
by parents, pending institutional requirements, or per investigator's opinion, would
prevent the subject from completing one course of pegcrisantaspase.

Pregnant or lactating females or females of childbearing potential not willing to use an
adequate method of birth control for the duration of the study. Female subjects who are
lactating who do not agree to stop breast-feeding.